Cipla Q4FY25 Results Preview: Strong show seen with margin boost; US biz, gRevlimid key triggers
Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based growth across geographies and improved margins, according to Zee Business Research. The Mumbai-based drugmaker is scheduled to announce its Q4FY25 earnings on May 13. Strong topline, robust operational gains expected Cipla’s consolidated revenue is…
